Reverse Transcriptase Inhibitors

1.	Cignarelli, Mauro: 3 articles (06/2008 - 10/2005)
2.	Barone, Carlo: 3 articles (06/2008 - 10/2005)
3.	Landriscina, Matteo: 3 articles (06/2008 - 10/2005)
4.	Wang, Xin: 3 articles (01/2005 - 01/2003)
5.	Lewis, William: 3 articles (01/2005 - 01/2003)
6.	Baba, Masanori: 3 articles (01/2005 - 01/2003)
7.	Piscazzi, Annamaria: 2 articles (06/2008 - 10/2005)
8.	Nelson, Mark: 2 articles (01/2008 - 07/2003)
9.	Phanuphak, Praphan: 2 articles (11/2007 - 09/2003)
10.	Spadafora, Corrado: 2 articles (01/2007 - 10/2005)

Related Diseases

1.	Acquired Immunodeficiency Syndrome (AIDS) 11/01/2008 - "TIBO (Tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepinone) compounds are potent non-nucleoside reverse transcriptase inhibitors (NNRTIs) that show a great promise for the treatment of AIDS. " 09/01/2001 - "CONCLUSION: EFV in combination with nucleoside reverse transcriptase inhibitors as antiretroviral therapy was potent and effective in reducing viral load, mainly in treating therapy-naïve patients and in preventing AIDS-defining events." 02/01/2004 - "At study entry, neuropathy (n=64) was associated with acquired immunodeficiency syndrome (AIDS), nucleoside analogue reverse transcriptase inhibitors (NRTI) (i.e. " 11/01/2000 - "A recent report suggesting mitochondrial dysfunction among eight HIV-exposed but uninfected children exposed perinatally to nucleoside reverse transcriptase inhibitors (NRTIs) prompted a review within the Perinatal AIDS Collaborative Transmission Study (PACTS). " 04/23/2008 - "RESULTS: Differences in estimated rates of transmitted drug resistance using International AIDS Society-USA, calibrated population resistance, Stanford 30, ANRS 1, Rega 1 and Rega 2 methods were mostly minor for resistance to protease and non-nucleoside reverse transcriptase inhibitors (1% range) and more pronounced for nucleoside reverse transcriptase inhibitors (5% range). " Order ALL the reference details at left...
2.	HIV Infections (HIV Infection) 05/01/2000 - "Four factors have contributed to this: an improved understanding of the pathogenesis of HIV infection; the availability of tests that could measure plasma viral burden; the development of new and more powerful drugs such as the protease and non-nucleoside reverse transcriptase inhibitors; and the completion of large clinical endpoint trials that conclusively demonstrated that potent antiretroviral combinations significantly delayed the progression of HIV disease and improved survival. " 07/01/2008 - "Improving non-nucleoside reverse transcriptase inhibitors for first-line treatment of HIV infection: the development pipeline and recent clinical data." 10/01/2007 - "This article gives an overview of the most relevant information from clinical trials, cohort studies and databases concerning backbones consisting of two nucleoside/nucleotide reverse transcriptase inhibitors in the treatment of HIV infections, as well as a description of the interactive decision matrix technique. " 07/18/2002 - "Virtually all the compounds that are currently used, or are subject of advanced clinical trials, for the treatment of human immunodeficiency virus (HIV) infections, belong to one of the following classes: (i) nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs): i.e. " 06/01/2008 - "OBJECTIVE: The purpose of this paper was to determine whether antiretroviral medications, especially the nucleoside analogue reverse transcriptase inhibitors, lead to altered brain activation due to their potential neurotoxic effects in patients with human immunodeficiency virus (HIV) infection. " Order ALL the reference details at left...
3.	Infection 04/01/2009 - "Following treatment of hepatitis B virus (HBV) infection with nucleos(t)ide reverse transcriptase inhibitors (NRTIs), there is a biphasic clearance of HBV, similar to that seen following treatment of human immunodeficiency virus-1 (HIV-1) and hepatitis C virus. " 04/01/2008 - "Potent PrEP regimens with reverse transcriptase inhibitors can prevent detectable SHIV infection in a repeated low-dose macaque model that resembles human transmission, supporting plans to quickly move this approach into human trials. " 03/01/2008 - "Key clinical trials of non-nucleoside reverse transcriptase inhibitors in the treatment of chronic HIV-1 infection in adults." 09/01/2000 - "Twenty-four subjects with advanced HIV-1 infection (CD4(+) T-cell count, <100/microl) and stable viral loads were studied using blood plasma samples collected over a study period of approximately 9 months, during which time most of the subjects were treated with reverse transcriptase inhibitors. " 11/12/1999 - "A randomized trial comparing regimens of four reverse transcriptase inhibitors given together or cyclically in HIV-1 infection--the Quattro Trial. " Order ALL the reference details at left...
4.	Disease Progression 02/01/2000 - "First, several trials demonstrated that combination therapy of nucleoside reverse transcriptase inhibitors (NRTIs) is superior to monotherapy in extending survival and delaying disease progression. " 11/20/1997 - "The triple combination of antiviral medications comprising two reverse transcriptase inhibitors and a proteinase inhibitor has brought about an improvement in the quality of life of the patient together with a slowing down of disease progression. " 01/01/2005 - "Long-term analysis of the resistance development in HIV-1 positive patients treated with protease and reverse transcriptase inhibitors: correlation of the genotype and disease progression." 01/01/2004 - "Mutations linked to drug resistance, human immunodeficiency virus type 1 biologic phenotype and their association with disease progression in children receiving nucleoside reverse transcriptase inhibitors." 10/01/2001 - "BACKGROUND: With decreased rates of HIV mortality and disease progression attributable to treatment with nucleoside analogue reverse transcriptase inhibitors (NRTIs), attention has now become focused on the toxicities of these forms of treatment. " Order ALL the reference details at left...
5.	Neoplasms (Cancer) 10/18/2008 - "A longer surveillance, including differential analysis of the different cancer sites and various nucleoside reverse transcriptase inhibitors administered is warranted." 10/18/2008 - "Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors." 01/01/2007 - "Anti-tumor activity of non-nucleosidic reverse transcriptase inhibitors." 03/09/2007 - "Our results suggested that telomerase activity and telomere length may serve as markers for estimating the efficacy of cancer radiotherapy and reverse transcriptase inhibitors, such as AZT, may be used clinically as a new radiosensitizer in cancer radiotherapy." 03/01/2001 - "Combined highly active anti-retroviral therapy (HAART) with protease and reverse transcriptase inhibitors has modified the natural history of opportunistic infections and neoplasms in human immunodeficiency virus (HIV)-infected patients. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Protease Inhibitors (Protease Inhibitor)
2.	Saquinavir (Invirase)
3.	HIV Protease Inhibitors
4.	RNA (Ribonucleic Acid)
5.	Nelfinavir (Viracept)
6.	Lamivudine (3TC)
7.	RNA-Directed DNA Polymerase (Reverse Transcriptase)
8.	abacavir (Ziagen)
9.	tenofovir
10.	Anti-Retroviral Agents (Antiretroviral Agents)

Related Therapies and Procedures

1.	Highly Active Antiretroviral Therapy (HAART)
2.	Aftercare (After-Treatment)
3.	Drug Therapy (Chemotherapy)
4.	Therapeutics
5.	Chemoprevention

Best Treatments:
Research Summary Report
on Acquired Immunodeficiency Syndrome

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 1267 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>